April 2025 - Page 9 of 14

CD123 CAR T & Engineered NK Cells: Emerging Hope in R/R AML

By Mourabit Halima 2025.04.13

At EBMT 2025, Dr. Rémy Duléry (Dana-Farber Cancer Institute) presented highly promising data on novel immunotherapeutic strategies for relapsed/refractory AML. While CD123-targeted CAR T-cell therapy has shown limited long-term survival…

EBMT 2025 | Dr. Luca Vago Explores Mechanisms of Leukemia Relapse Post-Allogeneic Transplantation: From Biology to Treatment (and Back)

By Mourabit Halima 2025.04.12

At the opening plenary of EBMT 2025, Dr. Luca Vago (Italy) delivered a thought-provoking presentation on the biological complexity behind leukemia relapse after allogeneic hematopoietic cell transplantation (allo-HCT).

EBMT 2025 | Dr. Alice Bertaina Presents Promising Results from T-allo10 Immunotherapy in Pediatric and Young Adult Patients with Hematologic Malignancies

By Mourabit Halima 2025.04.12

At the EBMT 2025 Congress, Dr. Alice Bertaina (Stanford University, USA) presented encouraging Phase Ia data on T-allo10 immunotherapy following TCRαβ-depleted hematopoietic stem cell transplantation (HSCT) in pediatric and young adult patients with hematologic malignancies.

EBMT 2025 | Prof. Gandhi Damaj Shares Updated Consensus on Allogeneic Transplantation in Peripheral T-cell Lymphoma (PTCL)

By Mourabit Halima 2025.04.12

At this year’s EBMT Congress in Florence, Prof. Gandhi Damaj (Hematology Institute, Normandy University, France) presented the latest recommendations from the EBMT Practice Harmonisation and Guidelines Committee on allogeneic hematopoietic cell transplantation (allo-HCT) in PTCL.

Can minor histocompatibility antigens (mHAgs) unlock new predictive power in GvHD risk stratification?

By Peng Longmei 2025.04.12

At EBMT 2025, Dr. Nicoletta Cieri (Dana-Farber Cancer Institute) delivered a forward-looking presentation exploring the prognostic potential of mHAg load in allogeneic hematopoietic cell transplantation (allo-HCT).Her findings suggest that systematic…

EBMT 2025 | GVHD Prophylaxis in Haploidentical HSCT for R/R AML: Insights from Dr. Giorgia Battipaglia

By Mourabit Halima 2025.04.12

At EBMT 2025, Dr. Giorgia Battipaglia shared important findings from a multicenter study comparing post-transplant cyclophosphamide (PTCy) versus antithymocyte globulin (ATG) as GVHD prophylaxis in patients with relapsed/refractory AML undergoing…

GVHD Prophylaxis in Intermediate-Risk AML: Mixed Results from a Multicenter Trial

By Mourabit Halima 2025.04.12

At EBMT 2025, Dr. Edouard Forcade presented the results of a multicenter randomized trial comparing cyclosporine (CsA) alone versus CsA plus mycophenolate mofetil (MMF) in patients with intermediate-risk AML in…

ASCO GI 2025 | Prof. Ying Yuan & Prof. Kefeng Ding on BB+CAPOX in RAS-Mutant MSS mCRC

By Yin, Jiale 2025.04.12

At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.

ASCO GI 2025 | Spotlight on SHR1701 from Peking University Cancer Hospital

By Mourabit Halima 2025.04.11

At the ASCO GI 2025 Symposium in San Francisco, experts from Peking University Cancer Hospital presented new data on SHR1701, a PD-L1/TGF-βR2 fusion protein. The Phase III results showed both survival benefits and a reduction in chemotherapy-induced myelosuppression in advanced gastric and GEJ cancers.

Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL

By Mourabit Halima 2025.04.11

At EBMT 2025, Professor Sebastian Giebel shared key data from a real-world, multicenter study on CART19 therapy in 345 B-ALL patients. The study highlights how prior alloHCT exposure impacts survival…